Imperial College London
Portrait Picture

ProfessorMohamedShamji

Faculty of Medicine, National Heart & Lung Institute

Professor of Immunology and Allergy
 
 
 
//

Contact

 

+44 (0)20 7594 3476m.shamji99 Website

 
 
//

Location

 

Room 111Sir Alexander Fleming BuildingSouth Kensington Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Golebski:2021:10.1016/j.immuni.2020.12.013,
author = {Golebski, K and Layhadi, JA and Sahiner, U and Steveling-Klein, EH and Lenormand, MM and Li, RCY and Bal, SM and Heesters, BA and Vilà-Nadal, G and Hunewald, O and Montamat, G and He, FQ and Ollert, M and Fedina, O and Lao-Araya, M and Vijverberg, SJH and Maitland-van, der Zee A-H and van, Drunen CM and Fokkens, WJ and Durham, SR and Spits, H and Shamji, MH},
doi = {10.1016/j.immuni.2020.12.013},
journal = {Immunity},
pages = {291--307.e7},
title = {Induction of IL-10-producing type 2 innate lymphoid cells by allergen immunotherapy is associated with clinical response.},
url = {http://dx.doi.org/10.1016/j.immuni.2020.12.013},
volume = {54},
year = {2021}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - The role of innate immune cells in allergen immunotherapy that confers immune tolerance to the sensitizing allergen is unclear. Here, we report a role of interleukin-10-producing type 2 innate lymphoid cells (IL-10+ ILC2s) in modulating grass-pollen allergy. We demonstrate that KLRG1+ but not KLRG1- ILC2 produced IL-10 upon activation with IL-33 and retinoic acid. These cells attenuated Th responses and maintained epithelial cell integrity. IL-10+ KLRG1+ ILC2s were lower in patients with grass-pollen allergy when compared to healthy subjects. In a prospective, double-blind, placebo-controlled trial, we demonstrated that the competence of ILC2 to produce IL-10 was restored in patients who received grass-pollen sublingual immunotherapy. The underpinning mechanisms were associated with the modification of retinol metabolic pathway, cytokine-cytokine receptor interaction, and JAK-STAT signaling pathways in the ILCs. Altogether, our findings underscore the contribution of IL-10+ ILC2s in the disease-modifying effect by allergen immunotherapy.
AU  - Golebski,K
AU  - Layhadi,JA
AU  - Sahiner,U
AU  - Steveling-Klein,EH
AU  - Lenormand,MM
AU  - Li,RCY
AU  - Bal,SM
AU  - Heesters,BA
AU  - Vilà-Nadal,G
AU  - Hunewald,O
AU  - Montamat,G
AU  - He,FQ
AU  - Ollert,M
AU  - Fedina,O
AU  - Lao-Araya,M
AU  - Vijverberg,SJH
AU  - Maitland-van,der Zee A-H
AU  - van,Drunen CM
AU  - Fokkens,WJ
AU  - Durham,SR
AU  - Spits,H
AU  - Shamji,MH
DO  - 10.1016/j.immuni.2020.12.013
EP  - 307
PY  - 2021///
SN  - 1074-7613
SP  - 291
TI  - Induction of IL-10-producing type 2 innate lymphoid cells by allergen immunotherapy is associated with clinical response.
T2  - Immunity
UR  - http://dx.doi.org/10.1016/j.immuni.2020.12.013
UR  - https://www.ncbi.nlm.nih.gov/pubmed/33450188
UR  - https://www.sciencedirect.com/science/article/pii/S1074761320305410?via%3Dihub
UR  - http://hdl.handle.net/10044/1/86371
VL  - 54
ER  -
Download